Titus Thorne

Last Updated April 1, 2022

Titus Thorne

 April 1, 2022

Researchers curious about PT-141 side effects will note that this research chemical has been extensively tested and is an FDA-approved treatment for generalized hypoactive sexual desire disorder (HSDD) in premenopausal women.

This guide will outline what PT-141 is, the main benefits it offers, and everything that researchers need to know about its side effects before conducting further experiments. Those considering running an experiment with PT-141 should find full details of this chemical’s main side effects and how it has been dosed in past studies.

Qualified researchers looking to explore PT-141 will find a detailed guide to purchasing this peptide online and instructions for locking in the best prices and fastest shipping times.

Buy PT-141 from the #1 online Peptides vendor in the world.

Disclaimer: Peptides.org contains information about products that are intended for laboratory and research use only, unless otherwise explicitly stated. This information, including any referenced scientific or clinical research, is made available for educational purposes only. Peptides.org makes every effort to ensure that any information it shares complies with national and international standards for clinical trial information and is committed to the timely disclosure of the design and results of all interventional clinical studies for innovative treatments publicly available or that may be made available. However, research is not considered conclusive. Peptides.org makes no claims that any products referenced can cure, treat or prevent any conditions, including any conditions referenced on its website or in print materials.


What Is PT-141?

PT-141 – better known as bremelanotide – is a melanocortin receptor agonist that was recently approved by the US FDA for the treatment of generalized hypoactive sexual desire disorder (HSDD) in premenopausal women [1]. It was developed by Palatin Technologies and has since been out-licensed to AMAG Pharmaceuticals Inc., which holds the exclusive North American rights to develop and commercialize bremelanotide [2].

PT-141 is currently available in the US under the brand name “Vyleesi” as an on-demand, self-administered subcutaneous HSDD therapy [3]. It is also available online as a research chemical and may be purchased by researchers interested in conducting experiments.

We will look at some of the top benefits offered by PT-141 in the following section.


PT-141


Benefits of PT-141 | Top 5

Researchers in the early stages of planning experiments or clinical trials with PT-141 may be curious about the benefits offered by this peptide. The following top five benefits should help illuminate potential areas for further research.

1. Increases Sexual Desire in Premenopausal Women With Acquired HSDD

PT-141’s top benefit – and the basis for its FDA approval – is that it increases sexual desire in premenopausal women with acquired HSDD. Successful Phase 2 and Phase 3 clinical trials have shown that bremelanotide has a “modest” yet “statistically significant” impact on patients’ sexual desire when self-administered up to 2 hours prior to intercourse [2].

The latest research into PT-141 indicates that it stimulates the release of dopamine [4], but its exact role in increasing female desire remains a fruitful avenue for further research.

2. Increases Sexual Satisfaction in Patients With HSDD

Besides increasing sexual desire, PT-141 also appears to increase overall sexual satisfaction in female patients. Phase 2 and 3 clinical trials have found that premenopausal women with HSDD experienced a greater frequency of “satisfying sexual events” after self-administering PT-141, compared with women who took a placebo [5].

In a 2016 trial, women who took 1.75 mg of PT-141 45 minutes before intercourse registered a +3.6 increase in sexual satisfaction according to their Female Sexual Function Index-desire domain score. The 12-week trial also found that lower doses of PT-141 (1.25mg) were effective but to a much lesser extent, with women reporting a +0.7 increase on average [5].

3. Lowers Intercourse-related Distress in Patients WithHSDD

A key benefit of PT-141 is its ability to lower distress related to low sexual desire when taken by premenopausal women with acquired HSDD. This finding comes from two identical Phase 3 placebo-controlled clinical trials where female patients with HSDD were asked questions related to a Female Sexual Distress Scale-Desire/Arousal/Orgasm assessment. Both trials found that women felt “significantly less distress” after taking PT-141, compared with patients who received a placebo [6].

4. Potential Erectile Dysfunction Treatment for Male Patients With Insufficient Response to Sildenafil

Although PT-141’s only indicated use is to treat premenopausal women with acquired HSDD, a 2004 study found that it created a “statistically significant erectile response” when administered to male patients with erectile dysfunction (ED) who had an insufficient response to sildenafil (Viagra) [7].

This research shows that further research in this area may highlight PT-141’s potential use as an ED therapy alongside other treatments like sildenafil.

5. Improves Intercourse Satisfaction in Male ED Patients

The fifth benefit of PT-141 is that it produces “considerably higher” levels of sexual satisfaction in male patients with ED, according to a 2008 study. The study found that 33.5% of the 342 married males who took part in the test experienced a “positive clinical result” after taking PT-141 [8].

Hopefully, this brief review of the top five benefits offered by PT-141 has highlighted potential areas for further research. It’s now time to turn our attention to the main focus of this guide; PT-141’s side effects.


PT-141 Side Effects

The main focus of this guide is PT-141 side effects and in this section, we’ll explore all documented adverse events related to this chemical’s use.

Overall, PT-141 is considered to be a safe and well-tolerated drug when taken at the prescribed doses. It is the second medication to be granted US FDA approval for the treatment of HSDD and can be prescribed to premenopausal women with acquired HSDD [2].

PT-141 is designed to be self-administered, as desired, by patients at least 45 minutes before sexual intercourse. As the method of delivery is subcutaneous injection, it may, in rare instances, cause minor injection-related side effects such as [2]:

  • Itching at or around the injection site
  • Swelling
  • General discomfort

However, these side effects are rare and were not reported at a rate deemed statistically significant during any phase 2 or 3 clinical trials involving PT-141.

According to data from Phase 2 clinical trials, patients reported minor adverse events (AEs) at the following rates [2]:

  • Headaches (11%)
  • Facial flushing (20.4%)
  • Nausea (39.9%)

According to the results of a longer phase 3 clinical trial, lasting 52-weeks, patients reported AEs at the following rates [9]:

  • Nausea (40.4%)
  • Headache (12.0%)
  • Flushing (20.6%)

The only serious AE to occur during long-term (open-label) PT-141 trials was nausea and it was not severe enough to warrant medical attention [9]. PT-141 does not interact adversely with ethanol and has no severe interactions with prescription medications.

Both phase 2 trials involving PT-141 dosed at 1.75 mg have concluded that it is “safe and well-tolerated”. It can be safely taken once per day up to a maximum of 8 times per month [10].

The latest PT-141 research has found that it can cause mild elevations in “serum enzyme” levels during therapy. It has also been linked to “acute liver injury in “rare” cases [11].

While PT-141’s side effects in premenopausal women with acquired HSDD have been thoroughly researched and are well understood, less is known about how it affects non-premenopausal women or male patients. It is not currently indicated to treat patients in these groups, however past trials have examined its effects in male patients.

In the above-cited 2004 study involving healthy male patients with ED and an insufficient response to Viagra, PT-141 was found to be “safe and well-tolerated” when taken at doses of up to 10 mg for 12 weeks [7].

In the 2008 study where male patients were given intranasal sprays of PT-141, researchers noted that it caused minor “drug-related adverse effects” including [8]:

  • Headaches
  • Nausea
  • Vomiting

The small sample sizes and short durations of these studies mean there is insufficient data to draw meaningful conclusions regarding PT-141. This clearly shows the need for further long-term clinical testing and draws attention to a possible avenue for further research [12].

Having reviewed the main known side effects of PT-141, and highlighted areas where further testing and clinical research is required, it’s time to consider the best vendor for qualified researchers interested in conducting research with this chemical.


Where To Buy PT-141 Online? | 2022 Guide

Researchers looking for a place to buy PT-141 online in 2022 will find full details of our preferred vendor in this section.

While PT-141 (bremelanotide) is a prescription medication in the United States, it is readily available online as a research chemical. Qualified researchers with the authority to conduct testing and clinical trials can purchase PT-141 online and have it shipped to their address.

Online, researchers can find multiple suppliers claiming to offer high-quality research-grade PT-141. But with so many suppliers to choose from, how can researchers know which one to trust?

In an attempt to answer that question, our team purchased PT-141 from a variety of reputable retailers. We graded each vendor on the quality of the peptide they provided, the value for money they offered, and the timeliness with which they delivered it. We also considered the security of their website, payment options, and customer support.

In our team’s view, Peptide Sciences is the best vendor offering PT-141 in 2022. It sells 99% pure PT-141 at unbeatable best prices and offers a great buying experience.

Here are a few things Peptide Science does phenomenally well:

  • Lab Tested Peptides: Many vendors claim to offer research-grade PT-141, but only Peptide Sciences has the evidence to prove that what they offer is 99% pure. They get each batch tested by an independent lab and then post the results on their website. This way, researchers can see the exact quality of what they are buying before making a purchase.
  • 14% Discount on Bulk Orders: Peptide Sciences charge just $47.5 for a 10mg vial of PT-141 but even with this low price, there’s no denying that running a long-term clinical trial isn’t cheap. Fortunately, researchers can get a further 14% discount when they purchase 10 vials of PT-141 or more, making research and experimentation with this chemical even more cost-effective.
  • Industry-leading Customer Support Team: Researchers wary about placing a large order of PT-141 with an online vendor will be pleased to know that Peptide Sciences has a team of industry-leading customer support specialists on hand to answer any queries or questions.
  • Fast, Free Shipping to the US: Researchers in the US will find that all shipping charges are waived on all orders over $100, while those based worldwide will find that shipping costs just $15. All orders over $300 get a complimentary 30 mL vial of bacteriostatic water.
  • Highly Secure Website: Our team loves the look and feel of the Peptide Science website. It’s secured with SSL technology so all personal data and payment information is kept confidential. Researchers can order in confidence from this vendor!

Researchers looking to run an experiment or clinical trial with PT-141 will find that Peptide Science is the best vendor by far. Our team found that they excel in all areas, from quality to cost, shipping, and security. They offer an incredibly simple, intuitive, hassle-free buying experience and are well worth checking out!

P.S. order your PT-141 today!


PT-141 Side Effects | Verdict

Researchers curious about PT-141’s side effects have hopefully found all their questions answered by this informative guide. Based on the available literature, PT-141 appears to be a safe, well-tolerated, FDA-approved treatment for HSDD in premenopausal women and has an excellent safety record. It has also been studied in small trials involving male patients and has also been found to be safe and produce few side effects.

Crucially, PT-141 is not known to interact adversely with alcohol or prescription drugs and appears to be a relatively safe chemical for conducting further research. We have outlined key areas, notably ED treatment, where a well-designed clinical trial involving PT-141 would illuminate more details regarding its safety in vivo testing.

Those planning to experiment with, or run clinical trials with PT-141 may consider contacting Peptide Science for a low-cost, reliable, trustworthy peptide vendor.


PT-141


References

  1. Dhillon S, Keam SJ. Bremelanotide: First Approval. Drugs. 2019 Sep;79(14):1599-1606. doi: 10.1007/s40265-019-01187-w. PMID: 31429064.
  2. Mayer D, Lynch SE. Bremelanotide: New Drug Approved for Treating Hypoactive Sexual Desire Disorder. Ann Pharmacother. 2020 Jul;54(7):684-690. doi: 10.1177/1060028019899152. Epub 2020 Jan 1. PMID: 31893927.
  3. Bremelanotide (Vyleesi) for hypoactive sexual desire disorder. Med Lett Drugs Ther. 2019 Jul 29;61(1577):114-116. PMID: 31381550.
  4. Pfaus JG, Sadiq A, Spana C, Clayton AH. The neurobiology of bremelanotide for the treatment of hypoactive sexual desire disorder in premenopausal women. CNS Spectr. 2021 Jan 18:1-9. doi: 10.1017/S109285292100002X. Epub ahead of print. PMID: 33455598.
  5. Clayton, A. H., Althof, S. E., Kingsberg, S., DeRogatis, L. R., Kroll, R., Goldstein, I., Kaminetsky, J., Spana, C., Lucas, J., Jordan, R., & Portman, D. J. (2016). Bremelanotide for female sexual dysfunctions in premenopausal women: a randomized, placebo-controlled dose-finding trial. Women's health (London, England), 12(3), 325–337. https://doi.org/10.2217/whe-2016-0018
  6. Kingsberg SA, Clayton AH, Portman D, Williams LA, Krop J, Jordan R, Lucas J, Simon JA. Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials. Obstet Gynecol. 2019 Nov;134(5):899-908. doi: 10.1097/AOG.0000000000003500. PMID: 31599840; PMCID: PMC6819021.
  7. Rosen, R. C., Diamond, L. E., Earle, D. C., Shadiack, A. M., & Molinoff, P. B. (2004). Evaluation of the safety, pharmacokinetics and pharmacodynamic effects of subcutaneously administered PT-141, a melanocortin receptor agonist, in healthy male subjects and in patients with an inadequate response to Viagra. International journal of impotence research, 16(2), 135–142. https://doi.org/10.1038/sj.ijir.3901200
  8. Safarinejad, M. R., & Hosseini, S. Y. (2008). Salvage of sildenafil failures with bremelanotide: a randomized, double-blind, placebo controlled study. The Journal of urology, 179(3), 1066–1071. https://doi.org/10.1016/j.juro.2007.10.063
  9. Simon JA, Kingsberg SA, Portman D, Williams LA, Krop J, Jordan R, Lucas J, Clayton AH. Long-Term Safety and Efficacy of Bremelanotide for Hypoactive Sexual Desire Disorder. Obstet Gynecol. 2019 Nov;134(5):909-917. doi: 10.1097/AOG.0000000000003514. PMID: 31599847; PMCID: PMC6819023.
  10. Althof S, Derogatis LR, Greenberg S, Clayton AH, Jordan R, Lucas J, Spana C. Responder Analyses from a Phase 2b Dose-Ranging Study of Bremelanotide. J Sex Med. 2019 Aug;16(8):1226-1235. doi: 10.1016/j.jsxm.2019.05.012. Epub 2019 Jul 2. PMID: 31277966.
  11. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012–. Bremelanotide. 2021 Aug 20. PMID: 34436837.
  12. Kim S, Cho MC, Cho SY, Chung H, Rajasekaran MR. Novel Emerging Therapies for Erectile Dysfunction. World J Mens Health. 2021 Jan;39(1):48-64. doi: 10.5534/wjmh.200007. Epub 2020 Mar 16. PMID: 32202086; PMCID: PMC7752520.

Table Of Contents